Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy

Clinical Cancer Research

Volumn 12, Issue 19, 2006, Pages 5794-5800

  Végran, Frédérique ^a   Boidot, Romain ^a   Oudin, Claire ^a   Riedinger, Jean Marc ^b   Bonnetain, Franck ^b   Lizard Nacol, Sarab ^a,b  

^a INSERM   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ALTERNATIVE SPLICING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASPASE 3; CASPASES; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ENZYME PRECURSORS; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; TUMOR CELLS, CULTURED;

EID: 33750309458     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0725     Document Type: Article

References (31)

1. Faraglia B, Bonsignore A, Scaldaferri F, et al. Caspase-3 inhibits the growth of breast cancer cells independent of protease activity. J Cell Physiol 2004;202:478-82.
2. Hortobagyi GN. The status of breast cancer management: challenges and opportunities. Breast Cancer Res Treat 2002;75:61-5.
3. Launay S, Hermine O, Fontenay M, et al. Vital functions for lethal caspases. Oncogene 2005;24:5137-48.
4. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
5. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000;407:810-6.
6. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 β-converting enzyme. J Biol Chem 1994;269:30761-4.
7. Janicke RU, Ng P, Sprengart ML, et al. Caspase-3 is required for α-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 1998;273:15540-55.
8. Janicke RU, Sprengart ML, Wati MR, et al. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273:9357-60.
9. Kurokawa H, Nishio K, Fukumoto H, et al. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. Oncol Rep 1999;6:33-7.
10. Yang XH, Sladek TL, Liu X, et al. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide induced apoptosis. Cancer Res 2001;61:348-54.
11. Stennicke HR, Salvesen GS. Properties of the caspases. Biochim Biophys Acta 1998;1387:17-31.
12. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15:2922-33.
13. Faleiro L, Lazebnik Y. Caspases disrupt the nuclear-cytoplasmic barrier. J Cell Biol 2000;151:951-9.
14. Tiso N, Pallavicini A, Muraro T, et al. Chromosomal localization of the human genes, CPP32, Mch2, Mch3, and lch-1, involved in cellular apoptosis. Biochem Biophys Res Commun 1996;225:983-9.
15. Huang Y, Shin NH, Sun Y, et al. Molecular cloning and characterization of a novel caspase-3 variant that attenuates apoptosis induced by proteasome inhibition. Biochem Biophys Res Commun 2001;283:762-9.
16. Devarajan E, Sahin AA, Chen JS, et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 2002;21:8843-51.
17. Essmann F, Engels IH, Totzke G, et al. Apoptosis resistance of MCF-7 breast carcinomas cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res 2004;64:7065-72.
18. Friedrich K, Wieder T, Von Haefen C, et al. Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 2001;20:2749-60.
19. Blanc C, Deveraux OL, Krajewski S, et al. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 2000;60:4386-90.
20. Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol 2001;60:1268-79.
21. O'Donovan N, Crown J, Stunell H, et al. Caspase 3 in breast cancer. Clin Cancer Res 2003;9:38-42.
22. Krajewski S, Krajewska M, Turner BC, et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999;6:29-40.
23. Vakkala M, Paakko P, Soini Y. Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion Br J Cancer 1999;81:592-9.
24. Hadjiloucas I, Gilmore AP, Bundred NJ, et al. Assessment of apoptosis in human breast tissue using an antibody against the active form of caspase-3: relation to tumor histopathological characteristics. Br J Cancer 2001;85:1522-6.
25. Mercatante D, Kole R. Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol Ther 2000;85:237-43.
26. Sazani P, Kole RJ. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing Clin Invest 2003;112:481-6.
27. Arnal M, Franco N, Fargeot P. et al. Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat 2000;61:13-20.
28. Lizard-Nacol S, Genne P, Coudert B, et al. MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients. Anticancer Res 1999;19:3575-81.
29. Chollet P Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Bri J Cancer 2002;86:1041-6.
30. Nakopoulo L, Alexandrou P, Stefanaki K, et al. Immunohistochemical expression of caspase-3 as an adverse indicator of the clinical outcome in human breast cancer. Pathobiology 2001;69:266-73.
31. Parton M, Krajewski S, Smith I, et al. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res 2002;8:2100-8.